Floatz Rating
CC41/100
Confidence
Indicative
Sponsor
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Modality
UNKNOWN
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
28Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06343402CT.gov Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Lung Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Bbo-8520 (this asset) | TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) | P1 | CC · 41 |
| Cis-Diamminedichloroplatinum Ii | Taiho Oncology, Inc. | P3 | BB |
| OTL-38 | On Target Laboratories, LLC | P4 | BB |
| Etoposide | SystImmune Inc. | P3 | BB |
| Carboplatin | SystImmune Inc. | P3 | B |
| Nivolumab | M.D. Anderson Cancer Center | P2 | B |
| Pembrolizumab | Essen Biotech | P2 | B |
| Lurbinectedin | SystImmune Inc. | P3 | B |
| Bl-M14D1 | SystImmune Inc. | P3 | B |
+42 more in the Lung Carcinoma cohort
Other indications for Bbo-8520
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Lung Cancer | — | P1 | CC · 43 |
| Non-Small Cell Lung Carcinoma | — | P1 | C · 36 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Bbo-8520 in Lung Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/bbo-8520-lung-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →